Loss of E-cadherin expression had greater prevalence in metastatic tumors (26/41, 63.4%) than in their matching primary tumors (10/41, 24.4%; P<0.05; Fig. 1 and Table IV). This evidence concerns the gene CDH1 and metastatic neoplasm.